Influence of aeroallergen sensitization and nasal polyposis on mepolizumab response in eosinophilic severe asthma
Aeroallergen
DOI:
10.2500/aap.2025.46.250003
Publication Date:
2025-02-27T04:31:02Z
AUTHORS (8)
ABSTRACT
Background: Studies on the impact of comorbidities treatment responses in severe eosinophilic asthma (SEA) are limited. This study was a real-world investigation into how presence or absence nasal polyps (NP) and sensitivity to aeroallergens influence outcomes mepolizumab therapy. Methods: In this retrospective study, data obtained from patients with SEA who received at least 6 months were analyzed. The initially divided two groups based NPs. Within these groups, further categorized subgroups according aeroallergen (AE). Asthma-related resulting four evaluated both before during follow-up period. Results: Among 36 NPs, 14 (38.8%) had AE (NP+AE+), whereas 22 (61.2%) did not (NP+AE‐). Of 35 without 17 (48.5%) (NP‐AE+), 18 (51.5%) (NP‐AE‐). independent AE, significantly associated an increase exacerbations oral corticosteroid (OCS) use (p < 0.001). NP+AE+ group, baseline Asthma Control Test (ACT) score lower, number hospitalizations higher After treatment, all showed significant reductions asthma-related exacerbations, hospitalizations, OCS use. Furthermore, ACT scores pulmonary function test parameters improved. There limited differences improvements among group showing reduction compared other Conclusion: Mepolizumab reduced different phenotypes. Analysis findings suggests that provides benefits regardless NPs AE.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (19)
CITATIONS (0)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....